- Home
- DATS vs LPTX Comparison
DATS vs LPTX Comparison
Compare DATS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- LPTX
- Stock Information
- Founded
- DATS 2014
- LPTX 2011
- Country
- DATS United States
- LPTX United States
- Employees
- DATS N/A
- LPTX N/A
- Industry
- DATS Computer Software: Prepackaged Software
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DATS Technology
- LPTX Health Care
- Exchange
- DATS Nasdaq
- LPTX Nasdaq
- Market Cap
- DATS 13.4M
- LPTX 14.7M
- IPO Year
- DATS 2021
- LPTX N/A
- Fundamental
- Price
- DATS $2.66
- LPTX $0.31
- Analyst Decision
- DATS
- LPTX Hold
- Analyst Count
- DATS 0
- LPTX 1
- Target Price
- DATS N/A
- LPTX N/A
- AVG Volume (30 Days)
- DATS 88.3K
- LPTX 661.1K
- Earning Date
- DATS 08-22-2025
- LPTX 08-19-2025
- Dividend Yield
- DATS N/A
- LPTX N/A
- EPS Growth
- DATS N/A
- LPTX N/A
- EPS
- DATS N/A
- LPTX N/A
- Revenue
- DATS $388.00
- LPTX N/A
- Revenue This Year
- DATS N/A
- LPTX N/A
- Revenue Next Year
- DATS N/A
- LPTX N/A
- P/E Ratio
- DATS N/A
- LPTX N/A
- Revenue Growth
- DATS N/A
- LPTX N/A
- 52 Week Low
- DATS $1.11
- LPTX $0.22
- 52 Week High
- DATS $9.34
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- DATS 55.66
- LPTX 43.86
- Support Level
- DATS $2.25
- LPTX $0.30
- Resistance Level
- DATS $2.46
- LPTX $0.37
- Average True Range (ATR)
- DATS 0.14
- LPTX 0.03
- MACD
- DATS 0.01
- LPTX -0.00
- Stochastic Oscillator
- DATS 87.00
- LPTX 28.53
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.